| Symbol | ATRA |
|---|---|
| Name | ATARA BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, California, 91320, United States |
| Telephone | +1 805 - 623-4211 |
| Fax | — |
| — | |
| Website | https://www.atarabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001604464 |
| Description | Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The companys product candidates comprise Tab-cel, ATA188, and CAR T Programs. Additional info from NASDAQ: |
Director Redmile Group, LLC 🟡 adjusted position in 3.2M shares (5 derivative) of Atara Biotherapeutics, Inc. (ATRA) at $0.00 Transaction Date: Jul 22, 2026 | Filing ID: 086733
Read moreNew Form SCHEDULE 13D/A - Atara Biotherapeutics, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001104659-26-086728 <b>Size:</b> 16 KB
Read moreNew Form 3 - Atara Biotherapeutics, Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0000905148-26-003168 <b>Size:</b> 3 KB
Read moreCherry Brian N 🟢 acquired 24.0K shares of Atara Biotherapeutics, Inc. (ATRA) Transaction Date: Jun 11, 2026 | Filing ID: 002951
Read moreNew Form 3 - Atara Biotherapeutics, Inc. <b>Filed:</b> 2026-06-15 <b>AccNo:</b> 0000905148-26-002950 <b>Size:</b> 9 KB
Read more(99% Neutral) ATARA BIOTHERAPEUTICS, INC. (ATRA) Announces New Board Appointment
Read moreNew Form S-8 - Atara Biotherapeutics, Inc. <b>Filed:</b> 2026-06-12 <b>AccNo:</b> 0001213900-26-068286 <b>Size:</b> 208 KB
Read moreHEIDEN WILLIAM K 🟢 acquired 12.0K shares of Atara Biotherapeutics, Inc. (ATRA) Transaction Date: Jun 09, 2026 | Filing ID: 002921
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02822495 | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus… | — | Epstein-Barr Virus (EBV) Infections | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03010332 | Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the… | — | CMV Viremia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT06429800 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participa… | Phase1 | Lupus Nephritis | Withdrawn | 2025-04-16 | 2025-04-16 | ClinicalTrials.gov |
| NCT06256484 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participa… | Phase1 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Terminated | 2024-09-06 | 2025-03-30 | ClinicalTrials.gov |
| NCT04577326 | Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma | Phase1 | Malignant Pleural Mesothelioma (MPM) | Active_Not_Recruiting | 2020-09-30 | 2026-09-30 | ClinicalTrials.gov |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr V… | Phase1 | Nasopharyngeal Carcinoma | Terminated | 2019-02-19 | 2021-08-19 | ClinicalTrials.gov |
| NCT03283826 | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With … | Phase1 | Primary Progressive Multiple Sclerosis | Terminated | 2017-10-19 | 2024-01-17 | ClinicalTrials.gov |
| NCT01646645 | Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of … | Phase2 | Cytomegalovirus | Completed | 2012-07-13 | 2019-12-11 | ClinicalTrials.gov |
| NCT01498484 | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a N… | Phase2 | EBV-induced Lymphomas | Completed | 2011-12-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT00620633 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukem… | Phase1 | Leukemia | Completed | 2008-02-08 | 2021-02-26 | ClinicalTrials.gov |
| NCT00002663 | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphopr… | Phase1 | EBV-induced Lymphomas | Completed | 1995-03-01 | 2019-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Primary Progressive Multiple Sclerosis | TERMINATED | NCT03283826 |
| ATA188 | Other | Phase PHASE1 | Primary Progressive Multiple Sclerosis | TERMINATED | NCT03283826 |
| Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs) | Other | Preclinical | CMV Viremia | NO_LONGER_AVAILABLE | NCT03010332 |
| CMV-pp65 CTLs | Other | Phase PHASE2 | Cytomegalovirus | COMPLETED | NCT01646645 |
| EBV-specific T cells (EBV-CTLs) | Other | Phase PHASE2 | EBV-induced Lymphomas | COMPLETED | NCT01498484 |
| tabelecleucel | Other | Preclinical | Epstein-Barr Virus (EBV) Infections | NO_LONGER_AVAILABLE | NCT02822495 |
| Pembrolizumab | Other | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03769467 |
| Tabelecleucel | Other | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03769467 |
| ATA3219 | Other | Phase PHASE1 | Lupus Nephritis | WITHDRAWN | NCT06429800 |
| CAR T cells | Other | Phase PHASE1 | Malignant Pleural Mesothelioma (MPM) | ACTIVE_NOT_RECRUITING | NCT04577326 |
| cyclophosphamide | Other | Phase PHASE1 | Malignant Pleural Mesothelioma (MPM) | ACTIVE_NOT_RECRUITING | NCT04577326 |
| ATA3219 | Other | Phase PHASE1 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | TERMINATED | NCT06256484 |
| ATA3219 | DRUG | Phase PHASE1 | Lupus Nephritis | WITHDRAWN | NCT06429800 |
| CAR T cells | BIOLOGICAL | Phase PHASE1 | Malignant Pleural Mesothelioma (MPM) | ACTIVE_NOT_RECRUITING | NCT04577326 |
| cyclophosphamide | DRUG | Phase PHASE1 | Malignant Pleural Mesothelioma (MPM) | ACTIVE_NOT_RECRUITING | NCT04577326 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03769467 |
| Tabelecleucel | BIOLOGICAL | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03769467 |
| Placebo | DRUG | Phase PHASE1 | Primary Progressive Multiple Sclerosis | TERMINATED | NCT03283826 |
| ATA188 | BIOLOGICAL | Phase PHASE1 | Primary Progressive Multiple Sclerosis | TERMINATED | NCT03283826 |
| Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs) | BIOLOGICAL | Preclinical | CMV Viremia | NO_LONGER_AVAILABLE | NCT03010332 |
| tabelecleucel | BIOLOGICAL | Preclinical | Epstein-Barr Virus (EBV) Infections | NO_LONGER_AVAILABLE | NCT02822495 |
| CMV-pp65 CTLs | BIOLOGICAL | Phase PHASE2 | Cytomegalovirus | COMPLETED | NCT01646645 |
| EBV-specific T cells (EBV-CTLs) | BIOLOGICAL | Phase PHASE2 | EBV-induced Lymphomas | COMPLETED | NCT01498484 |
| WT1-sensitized T cells | BIOLOGICAL | Phase PHASE1 | Leukemia | COMPLETED | NCT00620633 |
| Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | BIOLOGICAL | Phase PHASE1 | EBV-induced Lymphomas | COMPLETED | NCT00002663 |